MYC and cancer: Recently, Omomyc, a peptide that competitively binds to E-box elements as a heterodimer with MAX or as a homodimer and suppresses the binding of MYC to E-boxes (77–79), has been shown to have therapeutic potential in vivo in various cancer models (77, 79, 80).